Incidence of skeletal-related events in patients with breast or prostate cancer-induced bone metastasis or multiple myeloma: A 12-year longitudinal nationwide healthcare database study

Baek, Yeon‐Hee; Jeon, Ha‐Lim; Oh, In‐Sun; Yang, Hyowon; Park, Jeehye; Shin, Ju‐Young

doi:10.1016/j.canep.2019.05.013

Cited by 41 publications

(26 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are similar to our results in patients with stomach or liver cancer. The most common SRE was radiation therapy (31.7%), which has been frequently reported in other Korean studies [ 26 , 27 ], but is less frequently reported in other countries [ 2 , 28 ]. The second commonest SRE was pathologic fracture, accounting for 10.9% of the cases, and more than half of these SREs were fractures of the spine or pelvis.…”

Section: Discussionmentioning

confidence: 84%

“…In contrast, in breast and prostate cancers, bone metastases developed in the middle of the disease course. Since, patients with these cancers tended to live for more than 1 year, and they had more chances of experiencing SREs [ 27 ]. Accordingly, a multidisciplinary team approach should be used for the management of breast and prostate cancer patients to provide supportive care for bone metastases along with potential aggressive treatment for SREs such as fractures and spinal cord compression.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Bone metastasis and skeletal-related events in patients with solid cancer: A Korean nationwide health insurance database study

et al. 2020

View full text Add to dashboard Cite

Bone is one of the most common sites of metastasis from advanced solid tumors. Bone metastasis is a leading cause of pain and increases the risk of skeletal-related events (SREs) in cancer patients. In addition to affecting the quality of life, it also increases the medical costs and mortality risk. We aimed to examine the occurrence of bone metastasis and SREs in Korean cancer patients using a nationwide health database. Using claims data from the National Health Insurance Service-National Sample Cohort (2002–2013), we extracted the data of bone metastasis patients diagnosed with any of the seven major cancers in Korea from January 2002 to December 2010. Selected SREs included pathologic fracture, spinal cord compression, radiation therapy, and palliative bone surgery. We used time-to-event analysis to estimate patient survival after bone metastasis. A total of 21,562 newly diagnosed cancer patients were identified; bone metastases developed in 1,849 patients (breast cancer, 18.8%; prostate cancer, 17.5%; lung cancer, 13.7%). The median time from primary cancer diagnosis to bone metastasis was 18.9 months. The cumulative incidence of SREs was 45.1% in all bone metastasis patients. The most common cancer type was lung cancer (53.4%), followed by liver (50.9%), prostate (45.9%), breast (43.6%), and colorectal (40.2%) cancers. Almost all SREs developed 1 month after bone metastasis, except in patients with breast and prostate cancers (median: 5.9 months in breast cancer and 4.7 months in prostate cancer). Survival duration after the development of bone metastasis was < 6 months in stomach, liver, colorectal, and lung cancer patients. Breast and prostate cancer patients survived for > 1 year after the occurrence of SREs. This study reveals the epidemiology of bone metastasis and SREs in Korean cancer patients, and the findings can be used to assess the actual bone health status of cancer patients.

show abstract

Section: Discussionmentioning

confidence: 84%

Section: Discussionmentioning

confidence: 99%

Bone metastasis and skeletal-related events in patients with solid cancer: A Korean nationwide health insurance database study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Bone metastases not only considerably reduce the OS but also the health-related quality of life due to pain, fatigue, and skeletal-related events (SREs) [8][9][10]. Several therapeutic strategies to specifically target this condition (e.g., bone-modifying agents) are currently available [9,[11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management

Venetis

Piciotti

Sajjadi

et al. 2021

Cells

View full text Add to dashboard Cite

Despite the remarkable advances in the diagnosis and treatment of breast cancer patients, the presence or development of metastasis remains an incurable condition. Bone is one of the most frequent sites of distant dissemination and negatively impacts on patient’s survival and overall frailty. The interplay between tumor cells and the bone microenvironment induces bone destruction and tumor progression. To date, the clinical management of bone metastatic breast cancer encompasses anti-tumor systemic therapies along with bone-targeting agents, aimed at slowing bone resorption to reduce the risk of skeletal-related events. However, their effect on patients’ survival remains controversial. Unraveling the biology that governs the interplay between breast neoplastic cells and bone tissue would provide means for the development of new therapeutic agents. This article outlines the state-of-the art in the characterization and targeting the bone metastasis in breast cancer, focusing on the major clinical and translational studies on this clinically relevant topic.

show abstract

“…Bone metastases (BM) can cause a series of skeletal-related events (SREs), including pain, bone fractures, spinal cord compression and hypercalcemia [3, 4]. The incidence of SRE has been reported in several studies, the cumulative SRE incidences were respectively reported to be 47, 31.4, and 38.0% in breast cancer, prostate cancer and multiple myeloma patients [5]. Another study reported SRE in 26% patients with prostate cancer, 70% in renal cell carcinoma, and 58% in urothelial carcinoma [6].…”

Section: Introductionmentioning

confidence: 99%

Female sex is associated with a lower risk of bone metastases and favourable prognosis in non-sex-specific cancers

Peltzer

et al. 2019

BMC Cancer

View full text Add to dashboard Cite

BackgroundThe objectives were to investigate the disparity in the prevalence of bone metastases (BM) between the sexes and to assess the effect of female sex on the development and prognosis of BM.MethodsCases of invasive non-sex-specific cancers diagnosed between 2010 and 2015 in the Surveillance, Epidemiology, and End Results (SEER) program were used. The prevalence of BM was calculated by combining the prevalence of BM among different cancers. Multivariable logistic regression and proportion hazard regression were conducted to investigate the effect of female sex, and the results were pooled by meta-analysis.ResultsThe pooled prevalence of BM among male and female patients was 2.3% (95% CI: 1.6–3.2%) and 1.8% (95% CI: 1.2–2.6%), respectively. The pooled prevalence of BM dramatically decreased for patients aged 11–40 years old, plateaued for patients aged 41–90 years old and increased for patients aged > 90 years old in both male and female patients. Meta-analysis suggested that female sex had a protective effect on the development of BM (pooled OR = 0.80; 95% CI: 0.75–0.84; p < .001) and a favourable prognosis for respiratory system cancers (pooled HR = 0.81; 95% CI: 0.71–0.92; p < .001). However, no significant associations existed for other cancers. Male non-sex-specific cancer patients and those with male-leaning genetic variations or hormonal status have a greater likelihood of developing BM than female patients.ConclusionsFemale sex was associated with fewer BM in various non-sex-specific cancers, and the effect was constant with changes in age. Female sex showed a protective effect exclusively on the prognosis of respiratory system cancers.

show abstract

Incidence of skeletal-related events in patients with breast or prostate cancer-induced bone metastasis or multiple myeloma: A 12-year longitudinal nationwide healthcare database study

Cited by 41 publications

References 28 publications

Bone metastasis and skeletal-related events in patients with solid cancer: A Korean nationwide health insurance database study

Bone metastasis and skeletal-related events in patients with solid cancer: A Korean nationwide health insurance database study

Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management

Female sex is associated with a lower risk of bone metastases and favourable prognosis in non-sex-specific cancers

Contact Info

Product

Resources

About